Literature DB >> 21463231

Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis.

Haruki Koike1, Rina Hashimoto, Minoru Tomita, Yuichi Kawagashira, Masahiro Iijima, Fumiaki Tanaka, Gen Sobue.   

Abstract

Transthyretin (TTR) Val30Met-associated familial amyloid polyneuropathy (FAP ATTR Val30Met) is the most common form of FAP and is now prevalent in areas other than those seen within conventional endemic foci. We investigated 15 patients with FAP ATTR Val30Met without a family history of FAP who were referred for sural nerve biopsy. Initial symptoms included somatic neuropathy in all patients, while sensory dissociation and autonomic symptoms were apparent only in two and seven patients, respectively. Nonspecific neuropathic features and slight abnormalities in cerebrospinal fluid protein levels and in electrophysiological indices related to nerve conduction led clinicians to initially suspect chronic inflammatory demyelinating polyneuropathy (CIDP) in some patients. Small-fiber predominant loss was observed in a minority of patients. In terms of cardiac involvement, findings suggestive of subclinical cardiomyopathy due to amyloid deposition, such as cardiomegaly on chest X-ray, thickening of the interventricular septum, and granular sparkling echo on echocardiography, were seen alone or in combination in 11 of 14 examined patients. In conclusion, clinicians should consider the possibility of FAP ATTR Val30Met in patients presenting with neuropathy of undetermined etiology to avoid misdiagnosis. Detecting subclinical cardiac involvement may help to diagnose late-onset FAP ATTR Val30Met in those without a family history of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463231     DOI: 10.3109/13506129.2011.565524

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  29 in total

1.  TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.

Authors:  Marco Luigetti; Amelia Conte; Alessandra Del Grande; Giulia Bisogni; Francesca Madia; Mauro Lo Monaco; Luca Laurenti; Laura Obici; Giampaolo Merlini; Mario Sabatelli
Journal:  Neurol Sci       Date:  2012-05-17       Impact factor: 3.307

Review 2.  Acquired neuropathies.

Authors:  Pierre Lozeron; Jean-Marc Trocello; Nathalie Kubis
Journal:  J Neurol       Date:  2013-06-16       Impact factor: 4.849

3.  Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.

Authors:  Taro Yamashita; Mitsuharu Ueda; Yohei Misumi; Teruaki Masuda; Toshiya Nomura; Masayoshi Tasaki; Kotaro Takamatsu; Keiko Sasada; Konen Obayashi; Hirotaka Matsui; Yukio Ando
Journal:  J Neurol       Date:  2017-11-24       Impact factor: 4.849

Review 4.  [Hereditary transthyretin amyloidosis].

Authors:  E Hund
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

5.  Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.

Authors:  Anuja Roy; Andrew Peterson; Nick Marchant; Jose Alvir; Rahul Bhambri; Jason Lynn; Darrin Benjumea; Sapna Prasad; Alex O'Brien; Yong Chen; Jason Kemner; Bhash Parasuraman
Journal:  Patient Prefer Adherence       Date:  2022-04-29       Impact factor: 2.314

6.  Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  Haruki Koike; Tomohiko Nakamura; Atsushi Hashizume; Ryoji Nishi; Shohei Ikeda; Yuichi Kawagashira; Masahiro Iijima; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-10-05       Impact factor: 4.849

Review 7.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

Review 8.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

9.  Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.

Authors:  Ernst Hund
Journal:  Appl Clin Genet       Date:  2012-06-18

10.  Light-chain cardiac amyloidosis with neuropathy: a case report.

Authors:  Zhan-Wen Xu; Ya-Qin Li; Li-xia Liu; Bing-Juan Zhou
Journal:  Clin Interv Aging       Date:  2015-07-31       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.